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2'-O-fucosyllactose as novel food ingredients  
in food supplements for children 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
Abstract 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on the safety of lacto-N-neotetraose and 
2'-O-fucosyllactose as novel food ingredients in food supplements for children (excluding infants). In 
July 2015, the Panel concluded that LNnT and 2’-FL are safe for infants and for young children when 
added to infant, follow-on and young-child formulae under specific conditions of use; and for adults 
when added to foods at the uses and use levels proposed by the applicant, which include food 
supplements at a maximum intended daily intake of 1.5 g for LNnT and 3 g for 2’-FL. The applicant 
also intends to include LNnT and 2’-FL in food supplements for children, with maximum daily intake 
levels of 0.6 g for LNnT and 1.2 g for 2’-FL for toddlers (1–3 years of age), and maximum daily intake 
levels of 1.5 g for LNnT and 3 g for 2’-FL for children (4–18 years of age). In this scientific 
assessment, maximum daily intakes from food supplements for toddlers, children and teenagers are 
presented and two scenarios are calculated in which the maximum daily intakes from food 
supplements are added to the mean and 95th percentile intake estimates from all foods in which LNnT 
and 2’-FL are intended to be added. The Panel concludes that LNnT and 2’-FL are safe for the 
proposed use in food supplements at the maximum use levels proposed for toddlers (1–3 years of 
age) of 0.6 g/day for LNnT and 1.2 g/day for 2’-FL (alone or in combination) and for children (4-18 
years of age) of 1.5 g for LNnT and 3 g for 2’-FL (alone or in combination). However, in children of 
1-10 years of age the combined intakes from all foods in which the NFIs are intended to be added and 
from food supplements could result in intake levels which were reported to cause mild gastrointestinal 
symptoms in adults.  
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Summary 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on the safety of lacto-N-neotetraose and 
2'-O-fucosyllactose as novel food ingredients (NFIs) in food supplements for children (excluding 
infants).  
In July 2015, the Panel concluded that LNnT and 2’-FL are safe for infants and for young children 
when added to infant, follow-on and young-child formulae under specific conditions of use; and for 
adults when added to foods at the uses and use levels proposed by the applicant, which include food 
supplements at a maximum intended daily intake of 1.5 g for LNnT and 3 g for 2’-FL. 
The applicant also intends to include LNnT and 2’-FL in food supplements for children, with maximum 
daily intake levels of 0.6 g for LNnT and 1.2 g for 2’-FL for toddlers (1-3 years of age), and maximum 
daily intake levels of 1.5 g for LNnT and 3 g for 2’-FL for children (4-10 years of age) and teenagers 
(11-18 years of age).  
In this scientific assessment, maximum daily intakes from food supplements for toddlers, children and 
teenagers are presented and two scenarios for each population group are calculated in which the 
maximum daily intakes from food supplements are added to the mean and 95th percentile intake 
estimates (on a per kg body weight basis) from all foods in which LNnT and 2’-FL are intended to be 
added.  
For children at the considered age from 1 to 18 years, daily intakes from food supplements at the 
proposed maximum levels would be below the 95th percentile daily intakes estimated for LNnT and 
2’FL from all proposed foods intended to contain these NFIs, which were already considered safe by 
the Panel in July 2015. 
In children of 1–10 years of age the combined intakes from all proposed foods, which are intended to 
contain the NFI, plus food supplements, could result in intake levels which were reported to cause 
mild gastrointestinal symptoms in adults.  
However, the Panel notes that the intake estimates are based on the conservative assumptions that 
all proposed food items consumed by an individual actually contain the NFI at the maximum specified 
level of use and that in addition to such intakes these ingredients are also consumed from food 
supplements at the maximum proposed intake levels. 
The Panel concludes that LNnT and 2’-FL are safe for the proposed use in food supplements at the 
maximum use levels proposed for toddlers (1–3 years of age) of 0.6 g/day for LNnT and 1.2 g/day for 
2’-FL (alone or in combination) and for children (4–18 years of age) of 1.5 g for LNnT and 3 g for 
2’-FL (alone or in combination). 
However, in children of 1–10 years of age the combined intakes from all foods in which the NFIs are 
intended to be added and from food supplements could result in intake levels which were reported to 
cause mild gastrointestinal symptoms in adults.  
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1. Introduction  
 Background  1.1.
In July 2015, EFSA published two Scientific Opinions on lacto-N-neotetraose and 2'-O-fucosyllactose 
as novel food ingredients (NFIs). Lacto-N-neotetraose (LNnT) and 2'-O-fucosyllactose (2’-FL) are 
synthetic oligosaccharides, which are intended to be used in infant and follow-on formulae, foods for 
special medical purposes for infants and young children and other foods for infants and young 
children, as well as in foods or food supplements for adults (EFSA NDA Panel, 2015a, b).  
The Panel concluded that LNnT and 2’-FL are safe for infants (up to one year of age) when added to 
infant and follow-on formulae, in combination, at concentrations up to 0.6 g/L of LNnT and up to 
1.2 g/L of 2’-FL, at a ratio of 1:2 in the reconstituted formulae; are safe for young children (older than 
one year of age) when added to follow-on and young-child formulae (alone or in combination), at 
concentrations up to 0.6 g/L of LNnT and up to 1.2 g/L of 2’-FL, at a ratio of 1:2. The Panel also 
concluded that LNnT and 2’-FL are safe when added to other foods at the uses and use levels 
proposed by the applicant, including food supplements for adults with a maximum intended daily 
intake of 1.5 g for LNnT and 3 g for 2’-FL. 
The Panel considered that the maximum intended daily intake of 1.5 g for LNnT and 3 g for 2’-FL in 
food supplements for adults were safe, even if consumed on top of the estimated 95th percentile daily 
intake of LNnT (3.3 g) and 2’-FL (5 g) from all foods which are intended to contain these ingredients. 
The Panel noted that the intake estimate is based on the conservative assumption that all proposed 
food items consumed by an individual actually contain the NFI at the maximum specified level of use. 
The conclusion on safety was substantiated by the results of a randomised clinical trial in healthy 
adults over two weeks which showed that once per day intakes of 5 g of LNnT or 10 g of 2’-FL were 
not associated with any undesirable effects (Unpublished study report, 2015; EFSA NDA Panel, 2015a, 
b). Intakes of 5 g of LNnT and 10 g of 2’-FL per day correspond to 71 and 143 mg/kg body weight 
(bw), respectively, considering 70 kg as default value for the bw of adults. At the end of the 
intervention, a significantly higher incidence of passing gas was reported by participants who 
consumed daily either 10 g or 20 g (286 mg/kg bw) of LNnT compared with the placebo group. For 2’-
FL, a significantly higher incidence of nausea, rumbling, bloating, passing gas, diarrhoea, loose stools 
and urgency was reported for participants who consumed daily the highest studied dose of 20 g of 2’-
FL when compared with the placebo group. Stool consistency scores on the Bristol Stool scale were 
not significantly different between the intervention and placebo groups. All adverse events were 
reported to be ‘mild’. 
 Terms of Reference as provided by the requestor 1.2.
Since the EFSA opinions have considered the intended use of LNnT and 2’-FL in food supplements 
only for adults, the Commission requested EFSA to assess the safety of these novel food ingredients in 
food supplements also for children (excluding infants). 
2. Data and Methodologies  
 Data 2.1.
The assessment of the safety of lacto-N-neotetraose and 2'-O-fucosyllactose consumed in food 
supplements for children is based on the scientific opinions on the safety of lacto-N-neotetraose and 
2'-O-fucosyllactose as novel food ingredients pursuant to Regulation (EC) No 258/97, the 
documentation provided to EFSA as indicated in those scientific opinions, and a letter provided by the 
applicant on 5 October 2015 as part of the mandate.  
 Methodologies 2.2.
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 
29 July 1997 concerning the scientific aspects and the presentation of information necessary to 
support applications for the placing on the market of novel foods and novel food ingredients and the 
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preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament 
and of the Council.  
3. Assessment 
In the information provided to EFSA, the applicant proposes 0.6 g/day of LNnT and 1.2 g/day of 2’-FL 
as the maximum daily intake levels from food supplements for toddlers (1–3 years of age). For 
children aged 4–10 years and teenagers (11–18 years of age) the same maximum daily intakes as 
intended for adults, i.e. 1.5 g for LNnT and 3 g for 2’-FL, were proposed. 
The intake estimate provided by the applicant was based on the estimates as presented in the two 
EFSA Opinions (EFSA NDA Panel, 2015a, b), taking into account additional intakes from food 
supplements for children aged 1–18 years. 
Table 1 and 2 provide figures from mean and 95th percentile intake estimates on a per kg bw basis 
for LNnT and 2’-FL based on UK national diet and nutrition survey (NDNS) consumption data and the 
use levels in foods as proposed by the applicant. In addition to these figures, which were already 
assessed and presented in the EFSA Opinions of 2015 (EFSA NDA Panel, 2015a, b), additional 
maximum intakes from food supplements are presented and two scenarios are calculated in which the 
maximum intakes from food supplements are added to the total intake (i.e. mean and 95th percentile 
intake estimates) from the proposed food categories for these two ingredients.    
 Toddlers (1–3 years of age) 3.1.
The maximum daily use levels intended by the applicant for food supplements for toddlers are 0.6 g 
for LNnT and 1.2 g for 2’-FL. 
3.1.1. Lacto-N-neotetraose 
In its Opinion on LNnT (EFSA NDA Panel, 2015a), the Panel considered that the estimated 95th 
percentile intake of LNnT for toddlers from the proposed food categories (132 mg/kg bw per day) was 
significantly below the estimated 95th percentile intake (330 mg/kg bw per day) for infants aged 4-6 
months based on UK NDNS consumption data. At the proposed maximum daily intake levels, food 
supplements could provide additional intakes of about 42 mg LNnT per kg bw for toddlers. The 
addition of the proposed maximum daily intake levels from food supplements to the mean and the 
95th percentile intake of LNnT from the proposed food categories would result in 105 and 175 mg/kg 
bw per day, respectively. The 95th percentile intake from the proposed food categories plus food 
supplements (175 mg/kg bw per day) would result in intakes of about half of the estimated 95th 
percentile daily intake for infants. The Panel notes that the 95th percentile intake from the proposed 
food categories plus food supplements (175 mg/kg bw per day) is moderately above the dose level 
(143 mg/kg bw per day) for which a study in healthy adult subjects reported a higher incidence of 
passing gas as compared with the placebo group (Unpublished study report, 2015; EFSA NDA Panel, 
2015a).  
3.1.2. 2'-O-fucosyllactose  
In its Opinion on 2’-FL (EFSA NDA Panel, 2015b), the Panel considered the estimated 95th percentile 
intake of 2’-FL for toddlers from the proposed food categories (247 mg/kg bw per day) and the 95th 
percentile intake (209 mg/kg bw per day) for a 3-months old infant, based on consumption data from 
the EFSA Comprehensive Food Consumption Database. At the proposed maximum daily intake levels, 
food supplements could provide additional intakes of about 86 mg of 2’-FL per kg bw for toddlers. The 
addition of the proposed maximum daily intake levels from food supplements to the mean and the 
95th percentile intake of 2’-FL from the proposed food categories would result in 206 and 333 mg/kg 
bw per day, respectively. The 95th percentile intake from the proposed food categories plus food 
supplements (333 mg/kg bw per day) would be around 60% above the 95th percentile intake for a 3-
months old infant, based on consumption data from the EFSA Comprehensive Food Consumption 
Database (209 mg/kg bw per day). The Panel notes that the 95th percentile intake from the proposed 
food categories plus food supplements (333 mg/kg bw per day) is moderately above the dose level 
(286 mg/kg bw per day) for which a study in healthy adult subjects reported a higher incidence of 
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nausea, rumbling, bloating, passing gas, diarrhoea, loose stools and urgency as compared with the 
placebo group (Unpublished study report, 2015; EFSA NDA Panel, 2015b). 
 Children (4–10 years of age) 3.2.
The maximum daily use levels intended by the applicant for food supplements for children are 1.5 g 
for LNnT and 3 g for 2’-FL. 
3.2.1. Lacto-N-neotetraose 
Food supplements could provide an additional 60 mg of LNnT per kg bw per day on top of the 
estimated mean (31 mg) and the 95th percentile (72 mg) daily intakes from the proposed food 
categories, which could result in intakes of about 91 or 132 mg per kg bw, respectively. The Panel 
notes that the 95th percentile intake from the proposed food categories plus food supplements (132 
mg/kg bw per day) is close to the dose level (143 mg/kg bw per day) for which a study in healthy 
adult subjects reported a higher incidence of passing gas as compared with the placebo group 
(Unpublished study report, 2015; EFSA NDA Panel, 2015a). 
3.2.2. 2'-O-fucosyllactose  
Food supplements could provide an additional 120 mg of 2’-FL per kg bw per day on top of the 
estimated mean (58 mg) and the 95th percentile (135 mg) daily intakes from the proposed food 
categories, which could result in intakes of about 178 or 255 mg per kg bw, respectively. The Panel 
notes that the 95th percentile intake from the proposed food categories plus food supplements (255 
mg/kg bw per day) is close to the dose level (286 mg/kg bw per day) for which a study in healthy 
adult subjects reported a higher incidence of nausea, rumbling, bloating, passing gas, diarrhoea, loose 
stools and urgency as compared with the placebo group (Unpublished study report, 2015; EFSA NDA 
Panel, 2015b).  
 Teenagers (11–18 years of age) 3.3.
The maximum daily use levels intended by the applicant for food supplements for teenagers are 1.5 g 
for LNnT and 3 g for 2’-FL. 
3.3.1. Lacto-N-neotetraose 
Food supplements could provide an additional 26 mg of LNnT per kg bw per day on top of the 
estimated mean (13 mg) and the 95th percentile (35 mg) daily intakes from the proposed food 
categories, which could result in intakes of about 39 and 61 mg per kg bw per day, respectively. The 
Panel notes that these estimates are below the dose level (71 mg per kg bw per day) which was not 
associated with undesirable effects in a study in healthy adults and about half of the dose level (143 
mg per kg bw per day) for which a statistically significant higher incidence of passing gas was 
reported as compared with the placebo group (Unpublished study report, 2015; EFSA NDA Panel, 
2015a). 
3.3.2. 2'-O-fucosyllactose  
Food supplements could provide an additional 53 mg of 2’-FL per kg bw per day on top of the 
estimated mean (23 mg) and the 95th percentile (55 mg) daily intakes from the proposed food 
categories, which could result in intakes of about 76 or 108 mg per kg bw per day, respectively. The 
Panel notes that these estimates are below the dose level (143 mg per kg bw per day) which was not 
associated with undesirable effects in a study in healthy adults and about one third of the dose level 
(286 mg per kg bw per day) for which a statistically significant higher incidence of nausea, rumbling, 
bloating, passing gas, diarrhoea, loose stools and urgency was reported as compared with the placebo 
group (Unpublished study report, 2015; EFSA NDA Panel, 2015b).   
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Table 1:  Summary of the estimated daily per kg bw intake of LNnT from proposed food categories and food supplements by different population groups in 
the UK, based on data from NDNS  
Population 
groups 
Age group 
(years) 
All-user consumption (mg/kg bw per day) 
n Mean from 
proposed food 
categories 
95th percentile 
from proposed 
food categories 
Maximum 
proposed intakes 
from supplements 
Mean from proposed 
foods PLUS 
maximum food 
supplements 
95th percentile from 
proposed foods PLUS 
maximum food 
supplements 
Toddlers 1–3 219 63 132 42 105 175 
Children 4–10 423 31 72 60 91 132 
Teenagers 11–18 451 13 35 26 39 61 
Women of child-
bearing age 
19–40 216 13 53 23 36 76 
Female adults 19–64 460 13 40 26 39 66 
 
Table 2:  Summary of the estimated daily per kg bw intake of 2’-FL from proposed food categories and food supplements by different population groups in 
the UK, based on data from NDNS  
Population 
groups 
Age group 
(years) 
All-user consumption (mg/kg bw per day) 
n Mean from 
proposed food 
categories 
95th percentile 
from proposed 
food categories 
Maximum proposed 
intakes from 
supplements 
Mean from proposed 
foods PLUS 
maximum food 
supplements 
95th percentile from 
proposed foods PLUS 
maximum food 
supplements 
Toddlers 1–3 219 120  247  86 206 333 
Children 4–10 423 58 135 120 178 255 
Teenagers 11–18 451 23 55 53 76 108 
Women of child-
bearing age 
19–40 216 24 75 45 69 120 
Female adults 19–64 460 28 74 52 80 126 
  
Safety of LNnT and 2'-FL in food supplements for children 
 
 
 
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2015;13(11):4299 
 
4. Discussion  
For children at the considered age from 1 to 18 years, daily intakes from food supplements at the 
proposed maximum levels would be below the 95th percentile daily intakes estimated for LNnT and 
2’FL from all proposed foods intended to contain these NFIs, which were considered safe in the 
previous EFSA Opinions (EFSA NDA Panel, 2015a, b). 
For toddlers, adding the maximum proposed daily intakes from food supplements to the 95th 
percentile intakes from all proposed food categories considered in the EFSA Opinions on LNnT and 
2’-FL (EFSA NDA Panel, 2015a, b) would result in intakes of about half of the estimated 95th 
percentile daily intake for infants for LNnT (330 mg/kg bw) and around 60% above the estimated 
95th percentile daily intake for infants for 2’-FL (209 mg/kg bw), as considered in these EFSA 
Opinions. 
In children of 1-10 years of age such combined intakes from all proposed foods which are intended to 
contain the NFI plus food supplements, could result in intake levels (on a per kg body weight basis) 
which were reported to cause mild gastrointestinal symptoms in adults such as nausea, rumbling, 
bloating, passing gas, diarrhoea, loose stools and urgency. Since no human study has been provided 
on children other than infants, no conclusion can be made as to whether or at which dose levels 
children at this age would experience such symptoms.  
However, the Panel notes that the intake estimates are based on the conservative assumptions that 
all proposed food items consumed by an individual actually contain the NFI at the maximum specified 
level of use and that in addition to such intakes these ingredients are also consumed from food 
supplements at the maximum proposed intake levels. 
5. Conclusions 
The Panel concludes that LNnT and 2’-FL are safe for the proposed use in food supplements at the 
maximum use levels proposed for toddlers (1–3 years of age) of 0.6 g/day for LNnT and 1.2 g/day for 
2’-FL (alone or in combination) and for children (4–18 years of age) of 1.5 g for LNnT and 3 g for 
2’-FL (alone or in combination). 
However, in children of 1–10 years of age the combined intakes from all foods in which the NFIs are 
intended to be added and from food supplements could result in intake levels which were reported to 
cause mild gastrointestinal symptoms in adults.  
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Abbreviations 
bw body weight 
2’-FL 2'-O-fucosyllactose 
LNnT lacto-N-neotetraose 
NDNS national diet and nutrition survey 
NFI novel food ingredient 
  
 
 
